Evidence map›Paper›PMID 15309661›Full record

ReviewEmergency radiology2004

Acute treatment for ischemic stroke in 2004.

Yousef M Mohammad, Afshin A Divani, Jawad F Kirmani, Pansy Harris-Lane, Adnan I Qureshi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Emergency radiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yousef M MohammadDepartment of Neurology, Ohio State University, Columbus, Ohio, USA.
Afshin A Divani
Jawad F Kirmani
Pansy Harris-Lane
Adnan I Qureshi

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The last decade witnessed significant and unprecedented advances in the treatment of acute ischemic stroke. Intravenous tissue plasminogen activator and defibrinogenating agent are both now approved by the Food and Drug Administration for treatment of acute ischemic stroke within 3 h of symptom onset. Trials involving intra-arterial thrombolysis have demonstrated clinical benefit in patients treated within 6 h of symptom onset. The future for the development of new and better treatment for ischemic stroke looks very promising. Currently, induced hypothermia, laser evaporation, mechanical thrombectomy, angioplasty with stent placement, the combination of neuroprotective agents with thrombolysis, and the combination of intravenous with intra-arterial thrombolysis are being investigated.

Indexed as

AnticoagulantsBrain IschemiaClinical Trials as TopicFibrinolytic AgentsHumansHypothermia, InducedNeuroprotective AgentsPlatelet Aggregation InhibitorsStrokeThrombectomyThrombolytic TherapyTissue Plasminogen ActivatorAnticoagulantsFibrinolytic AgentsNeuroprotective AgentsPlatelet Aggregation InhibitorsTissue Plasminogen Activator

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.